文献速递胸部肿瘤放疗放疗物理与技术

局部晚期非小细胞肺癌PD-L1阴性或低表达患者的预后因素:PACIFIC试验后的真实世界数据分析

Locally advanced non-small cell lung cancer with negative or low programmed death ligand 1 expression: a prognostic factor analysis of real-world data after the PACIFIC trial.
PubMed 文献 · Radiat Oncol · 2025-10-16

本研究基于PACIFIC试验后的真实世界数据,纳入2017年3月至2022年5月在本机构接受根治性放疗的130例PD-L1阴性或低表达的局部晚期非小细胞肺癌患者,采用竞争风险分析评估癌症特异性死亡、复发、远处转移和野内复发的累积发生率。多因素分析显示,间质性肺异常(ILA)评分≥1是总生存期缩短和野内复发累积发生率升高的显著因素,平均心脏剂量≥7.5 Gy对总生存期缩短呈显著趋势。

要点

  • PD-L1阴性或低表达LA-NSCLC患者中,ILA评分≥1与更短OS和更高野内复发相关。
  • 平均心脏剂量≥7.5 Gy对更短OS呈显著趋势。
  • 内照射高剂量VMAT与更低复发累积发生率相关,基线体能状态差与更高远处转移相关。

核心结论

  • 治疗前间质性肺异常和高平均心脏剂量对PD-L1阴性或低表达LA-NSCLC患者的OS产生负面影响。

研究设计与样本

  • 回顾性真实世界研究,纳入2017年3月至2022年5月在本机构接受根治性放疗的130例PD-L1阴性或低表达LA-NSCLC患者。
  • 采用竞争风险分析评估癌症特异性死亡、复发、远处转移和野内复发的累积发生率。

主要发现

  • 中位随访37个月(范围2–72个月),54例(41.5%)死亡,其中49例死于肺癌,75例(57.7%)接受度伐利尤单抗治疗。
  • 多因素分析显示ILA评分≥1是OS缩短和CI-IFR升高的显著因素。
  • 平均心脏剂量≥7.5 Gy对OS缩短呈显著趋势。
  • 内照射高剂量VMAT与更低的CI-R相关,基线体能状态差与更高的CI-DM相关。
  • 度伐利尤单抗给药与更低的CI-R呈边缘性相关。

关键数值与推荐

  • ILA评分≥1:与更短OS和更高CI-IFR显著相关。
  • 平均心脏剂量≥7.5 Gy:对更短OS呈显著趋势。

临床怎么用

  • 对PD-L1阴性或低表达LA-NSCLC根治性放疗患者,应评估治疗前ILA评分和平均心脏剂量以识别预后不良风险。
  • 内照射高剂量VMAT可能降低复发累积发生率,基线体能状态差者需关注远处转移风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world data on patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiotherapy have been reported; however, prognostic factors in patients with negative or low programmed cell death ligand 1 (PD-L1) expression are unclear. Therefore, we aimed to explore prognostic factors in patients with LA-NSCLC with negative or low PD-L1 expression using real-world data obtained after the PACIFIC trial. METHODS: Patients with LA-NSCLC with negative or low PD-L1 expression who received definitive radiotherapy at our institution between March 2017 and May 2022 were included. Competing risk analyses were used to evaluate cumulative incidence of cancer-specific death (CI-CSD), cumulative incidence of recurrence (CI-R), cumulative incidence of distant metastasis (CI-DM), and cumulative incidence of in-field recurrence (CI-IFR). RESULTS: The study included the data of 130 patients. Median follow-up was 37 (range, 2–72) months after radiotherapy initiation; 54 (41.5%) patients died, among whom 49 died of lung cancer, and 75 (57.7%) received durvalumab. Multivariate analyses revealed that interstitial lung abnormality (ILA) score ≥ 1 was a significant factor of shorter OS and higher CI-IFR, and a mean heart dose ≥ 7.5 Gy showed a trend toward significance for shorter OS., Internal high-dose volumetric modulated arc therapy was associated with lower CI-R, whereas poor baseline performance status correlated with higher CI-DM. Notably, durvalumab administration was marginally associated with lower CI-R. CONCLUSIONS: Pre-treatment ILA and high mean heart doses negatively impacted OS in patients with LA-NSCLC with negative or low PD-L1 expression according to real-world data obtained after the PACIFIC trial.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kashihara T, Nakayama Y, Okuma K, et al. Locally advanced non-small cell lung cancer with negative or low programmed death ligand 1 expression: a prognostic factor analysis of real-world data after the PACIFIC trial. Radiat Oncol. 2025. PMID: 41102751. doi:10.1186/s13014-025-02733-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。